Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| 1,2-Dioleoyl-sn-glycerol | 1,2-Dioleoyl-sn-glycerol is an analog of the protein kinase C-activating second messenger DAG. Group: Pharmaceutical. CAS No. 24529-88-2. Pack Sizes: 100 mg. Product ID: B0084-203872. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| 1,4-Bis(4-nitrophenyl)piperazine | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 16264-05-4. Pack Sizes: 100 mg. Product ID: B1476-166965. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 17-DMAG hydrochloride | 17-DMAG hydrochloride (Alvespimycin hydrochloride) is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to Hsp90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Group: Pharmaceutical. CAS No. 467214-21-7. Pack Sizes: 100 mg. Product ID: BBF-05796. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 1-NA-PP1 | 1-NA-PP1 is a reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild-type kinase. Group: Pharmaceutical. CAS No. 221243-82-9. Pack Sizes: 25 mg. Product ID: B2693-102805. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ((1R,3R)-3-Amino-cyclopentyl)-carbamic Acid tert-Butyl Ester | ((1R,3R)-3-Amino-cyclopentyl)-carbamic Acid tert-Butyl Ester is used in the preparation of quinoline-3-carboxoamides as H-PGDS inhibitors as well as novel triazolo-pyrrolopyridines as Janus kinase 1 inhibitors. Group: Pharmaceutical. CAS No. 1009075-44-8. Pack Sizes: 1 g. Product ID: BB074488. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 2-((3-Iodo-1H-indazol-6-yl)thio)-N-methylbenzamide | An impurity of Axitinib, a tyrosine kinase inhibitor used for the treatment of kidney cancer. Group: Pharmaceutical. CAS No. 885126-34-1. Pack Sizes: 100 mg. Product ID: B2694-467100. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 2-butoxy-7-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]-5H-pyrrolo[3,2-d]pyrimidin-4-amine | 2-butoxy-7-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a medicinal molecule known for its kinase-inhibiting properties, has been identified as a potential candidate for cancer therapy due to its unique ability to induce apoptosis and inhibit the proliferation of malignant cells. With promising applications in the treatment of leukemia and lung cancer, this small-molecule inhibitor has the potential to address critical unmet clinical needs in cancer management. Its effectiveness and suitability as a therapeutic intervention call for further investigation in the field of oncology. Group: Pharmaceutical. CAS No. 1878111-20-6. Pack Sizes: 5 mg. Product ID: B0001-008679. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 2'-Deoxycytidine 3'-monophosphate ammonium salt | 2'-Deoxycytidine 3'-monophosphate ammonium salt is a nucleotide-like compound that is extensively employed in scientific research, especially in the disciplines of DNA sequencing and synthesis. Furthermore, it serves as an essential ingredient for various phosphatases and kinases. With its unique properties, it has the potential to combat a variety of viral infections and cancers, thus opening up new avenues for therapeutic interventions. Group: Pharmaceutical. CAS No. 102783-50-6. Pack Sizes: 20 mg. Product ID: B2001-297040. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| [(2S,6R)-6-{N4-Benzoylcydin-1-yl}-4-tritylmorpholin-2-yl]methyl dimethyl-phosphoramidochloridate | This product is a potent inhibitor of Abl kinases and was developed for the treatment of chronic myeloid leukemia (CML). It works by blocking the activity of the Bcr-Abl fusion protein, which drives the growth of CML cells. Clinical trials have shown promising results, with high rates of complete remission and durable responses in patients with CML who were resistant or intolerant to previous treatments. Group: Pharmaceutical. CAS No. 956139-21-2. Pack Sizes: 1 g. Product ID: B2706-339313. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3-((3R,4R)-4-methyl-3-(methylamino)piperidin-1-yl)-3-oxopropanenitrile hydrochloride | An impurity of Tofacitinib, a Janus kinase inhibitor that could be used against rheumatoid arthritis. Group: Pharmaceutical. CAS No. 1640971-87-4. Pack Sizes: 5 mg. Product ID: B2694-063174. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3-Ketosphingosine | 3-Ketosphingosine is a biomarker for Niemann-Pick disease type A and B, as well as for sphingosine kinase-associated inflammatory disorders. It is also used as a research tool for studying the metabolism and signaling pathways of sphingolipids in various biological processes. Group: Pharmaceutical. CAS No. 19767-16-9. Pack Sizes: 10 mg. Product ID: B1370-154089. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3-Methyladenine | 3-Methyladenine is an autophagy inhibitor that protects cerebellar granule cells (CGCs) from apoptosis following serum/potassium deprivation. 3-Methyladenine inhibits phosphoinositide 3-kinase (PI3K) activity, which plays a key role in autophagy process. Group: Pharmaceutical. CAS No. 5142-23-4. Pack Sizes: 250 mg. Product ID: B0084-070159. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine | 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine is a highly potent and selective protein kinase CK1ε inhibitor. Evidence suggests that this compound exhibits strong neuroprotective and anti-tumor activity, and holds great promise as a potential treatment for Alzheimer's disease and select cancers. Its unique chemical structure and mechanism of action make it an exciting candidate for further preclinical and clinical development. Group: Pharmaceutical. CAS No. 943736-58-1. Pack Sizes: 10 g. Product ID: B2699-100946. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 5,7-Dihydrox -4'-methoxyisoflavone | Biochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. Uses: Anti-tumorigenesis, anti-oxidation, and anti-inflammatory. Group: Pharmaceutical. CAS No. 491-80-5. Pack Sizes: 5 g. Product ID: NP1827. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 5-bromo-4-chloro-N-cyclopentylpyrimidin-2-amine | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 1823404-28-9. Pack Sizes: 100 mg. Product ID: B1476-284923. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Bromo-8-cyclopentyl-2-[[5-(4-Boc-1-piperazinyl)-2-pyridyl]amino]-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 571188-82-4. Pack Sizes: 100 mg. Product ID: B1476-282703. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl-6-Bromo Palbociclib | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 851067-56-6. Pack Sizes: 100 mg. Product ID: B1476-283285. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl-6-Bromo Palbociclib Hydrochloride | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 850918-83-1. Pack Sizes: 100 mg. Product ID: B1476-284929. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl Palbociclib | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 571190-22-2. Pack Sizes: 100 mg. Product ID: B1476-478511. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Desacetyl Palbociclib Hydrochloride | An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer. Group: Pharmaceutical. CAS No. 571189-66-7. Pack Sizes: 100 mg. Product ID: B1476-284928. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 6-Gingerol | 6-gingerol is the active constituent of fresh ginger. It is bioactive compound found in ginger (Zingiber officinale) with antioxidant activity, which functions as an anti-inflammatory and antitumor agent. It has been shown to inhibit COX-2 expression by blocking the activation of p38 MAP kinase and NF-κB in phorbol ester-stimulated mouse skin. lt may reduce nausea caused by motion sickness or pregnancy and may also relieve migraine. lt has been investigated for its effect on cancerous tumors in the bowel, breast tissue, ovaries, the pancreas, among other tissues, with positive results. Uses: Anti-inflammatory, antitumor and antioxidant activity. Group: Pharmaceutical. CAS No. 23513-14-6. Pack Sizes: 25 mg. Product ID: NP5162. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 9-ethyl-8-iodo-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | 9-Ethyl-8-iodo-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, a promising therapeutic agent for the treatment of select neoplastic disorders, functions as a highly proficient suppressor of pathogenic kinase enzymes that exhibit heightened expression levels in malignant neoplastic cells. This mechanism of action, whereby key cellular signaling pathways are disrupted, culminates in the prevention of tumor growth and impairs the metastatic process. Group: Pharmaceutical. CAS No. 1256584-80-1. Pack Sizes: 100 mg. Product ID: B2699-281515. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| A-83-01 | A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7) (IC50s = 12, 45, and 7.5 nM, respectively). It blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition. Group: Pharmaceutical. CAS No. 909910-43-6. Pack Sizes: 50 mg. Product ID: B0084-155117. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib | Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. CAS No. 1231929-97-7. Pack Sizes: 100 mg. Product ID: B0084-462724. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib-[13C4,15N2] | Abemaciclib-[13C4,15N2] is a labelled Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-014039. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib-[d10] | Labelled Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003175. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib-[d5] | Labelled Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. CAS No. 1809251-51-1. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003176. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib-[d7] | Labelled Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003177. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib-[d8] | Labelled Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003178. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib Impurity 1-[d12] | Abemaciclib Impurity 1-[d12] is a labelled impurity of Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003179. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib Impurity 1-[d5] | Abemaciclib Impurity 1-[d5] is a labelled impurity of Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003180. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abemaciclib Impurity 5-[d5] | Abemaciclib Impurity 5-[d5] is a labelled impurity of Abemaciclib. Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers. Group: Pharmaceutical. CAS No. 1809251-58-8. Pack Sizes: 1mg; 1g; 10g. Product ID: BLP-003181. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abl Cytosolic Substrate | Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl). Group: Pharmaceutical. CAS No. 168202-46-8. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-016269. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Abl Cytosolic Substrate acetate | Abl Cytosolic Substrate acetate is a substrate for Abelson tyrosine kinase (Abl). Group: Pharmaceutical. CAS No. 2918768-10-0. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-016268. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ABT 702 Dihydrochloride | ABT 702 Dihydrochloride is a potent and selective non-nucleoside adenosine kinase inhibitor with IC50 value of 1.7 nM. ABT 702 displays oral activity in animal models of pain and inflammation. In Mar 2005, ABT 702 was discontinued preclinical for Pain and Rheumatoid arthritis in USA. Uses: Anti-inflammation. Group: Pharmaceutical. CAS No. 1188890-28-9. Pack Sizes: 50 mg. Product ID: B2693-475131. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acalabrutinib | Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. Group: Pharmaceutical. CAS No. 1420477-60-6. Pack Sizes: 250 mg. Product ID: B0084-470855. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acalabrutinib-[d4] | Acalabrutinib-[d4] is a labelled version of Acalabrutinib. Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. Group: Pharmaceutical. Pack Sizes: 5 mg. Product ID: BLP-003188. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acetyl-α,β-dehydro-phenylalanine | A protein kinase C inhibitor. Group: Pharmaceutical. CAS No. 5469-45-4. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-002080. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acetyl-L-glutamic acid | A substrate for acetylglutamate kinase. An inhibitor of N-acetyl-L-glutamate synthetase. Group: Pharmaceutical. CAS No. 1188-37-0. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-003849. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acteoside | Verbascoside is a bioactive polyphenol from olive oil mill wastewater with known antioxidant activity, which is a protein kinase C inhibitor. Uses: Antineoplastic; antimetastatic;antimicrobial activity. Group: Pharmaceutical. CAS No. 61276-17-3. Pack Sizes: 100 mg. Product ID: NP5345. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AEE-788 | AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. Group: Pharmaceutical. CAS No. 497839-62-0. Pack Sizes: 10 mg. Product ID: B0084-258485. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Afatinib Impurities | Afatinib Impurities are critical for assessing the quality and safety of afatinib, a tyrosine kinase inhibitor used in treating non-small cell lung cancer. These impurities provide insights into the drug's stability and degradation pathways, ensuring therapeutic efficacy and compliance with rigorous pharmaceutical standards. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AG 126 | Tyrphostins are protein tyrosine kinase inhibitors developed to inhibit cell growth through blocking the activity of certain GFRK (growth factor receptor kinases). AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM. It also inhibits the production of TNF-α (tumor necrosis factor-α), attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in animal models. AG 126 is a poor inhibitor of epidermal GFRK with IC50 of 450 μM and platelet-derived GFRK with IC50 > 100 μM. AG 126 may represent a new approach for the therapy of inflammation. Uses: Anti- inflammation. Group: Pharmaceutical. CAS No. 118409-62-4. Pack Sizes: 100 mg. Product ID: B1370-195904. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AG-1557 | AG-1557 is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Group: Pharmaceutical. CAS No. 189290-58-2. Pack Sizes: 50 mg. Product ID: B0084-284805. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AG-879 | AG-879, a tyrphostin compound, is a dual EGFR/HER2 inhibitor that was administered together with androgen withdrawal therapy. It inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40 μM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 μM), and the VEGF receptor FLK1 (IC50 = ~1 μM). Group: Pharmaceutical. CAS No. 148741-30-4. Pack Sizes: 20 mg. Product ID: B0084-195953. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alectinib | Alectinib, marketed as Alecensa, is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib has a low potential for interactions. While it is metabolised by the liver enzyme CYP3A4, and blockers of this enzyme accordingly increase its concentrations in the body, they also decrease concentrations of the active metabolite M4, resulting in only a small overall effect. Conversely, CYP3A4 inducers decrease alectinib concentrations and increase M4 concentrations. Interactions via other CYP enzymes and transporter proteins cannot be excluded but are unlikely to be of clinical significance. Group: Pharmaceutical. CAS No. 1256580-46-7. Pack Sizes: 200 mg. Product ID: B0084-454466. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alisertib | MLN8237 is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Group: Pharmaceutical. CAS No. 1028486-01-2. Pack Sizes: 100 mg. Product ID: B2693-336876. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ALK5 Inhibitor II hydrochloride | ALK5 inhibitor II was identified as a cell permeable, selective inhibitor of the TGF-β type 1 activin like kinase receptor ALK5 (ALK5 autophosphorylation, IC50s = 4 nM, TGF-β cellular assay, IC50s = 18 nM, ALK5 binding in HepG2 cells, IC50s = 23 nM). This compound has been used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription. This product is a hydrochloride form. Group: Pharmaceutical. CAS No. 446859-33-2. Pack Sizes: 50 mg. Product ID: B0084-068993. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alpelisib | Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BYL719 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Group: Pharmaceutical. CAS No. 1217486-61-7. Pack Sizes: 100 mg. Product ID: B0084-457654. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| α-Amyloid Precursor Protein Modulator | α-Amyloid Precursor Protein Modulator is a cell-permeable protein kinase C (PKC) activator. It was shown to induce differentiation of hESCs into Pdx-1 expressing pancreatic progenitor cells. Group: Pharmaceutical. CAS No. 497259-23-1. Pack Sizes: 2.5 mg. Product ID: B0084-314011. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| α-Viniferin | α-Viniferin isolated from the herb of Carex humilis Leyss. It inhibits AChE activity is specific, reversible and noncompetitive,down-regulating STAT-1-inducible inflammatory genes via inhibiting ERK-mediated STAT-1 activation in IFN-gamma-stimulated macrophages. Uses: Anti-inflammatory activity; antifungal; inhibits protein kinase c; inhibits prostaglandin h2 synthase carex humilis. Group: Pharmaceutical. CAS No. 62218-13-7. Pack Sizes: 1 mg. Product ID: NP4646. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alsterpaullone | Alsterpaullone is a potent glycogen synthase kinase-3 inhibitor and a potential therapeutic agent for the treatment of Parkinson disease. Alsterpaullone is also known as 9-Nitropaullone and NSC 705701, which is a derivative of kenpaullone and an ATP-competitive inhibitor of several cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Alsterpaullone induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Alsterpaullone is a derivative of kenpaullone with slightly improved potency over kenpaullone, alsterpaullone selectively inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and GSK3α/β with IC50 values of 35, 15, 200, 40, and 4 nM, respectively. Group: Pharmaceutical. CAS No. 237430-03-4. Pack Sizes: 50 mg. Product ID: B2693-103248. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Altiratinib | Altiratinib, also known as DCC-270, DP-5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer activity. DCC-2701 effectively reduces tumor burden in vivo and blocks c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC-2701's anti-proliferative activity was dependent on c-MET activation induced by stromal human fibroblasts and to a lesser extent exogenous HGF. DCC-2701 may be superior to HGF antagonists that are in clinical trials and that pTyr(1349) levels might be a good indicator of c-MET activation and likely response to targeted therapy as a result of signals from the microenvironment. Group: Pharmaceutical. CAS No. 1345847-93-9. Pack Sizes: 50 mg. Product ID: B2693-463181. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AMG-3969 | AMG-3969 is a potent and selective disruptor of glucokinase-glucokinase regulatory protein interaction (GK-GKRP). AMG-3969 can modulate the blood glucose levels in rodent models of diabetes. Group: Pharmaceutical. CAS No. 1361224-53-4. Pack Sizes: 100 mg. Product ID: B0084-053994. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AMG-900 | AMG 900 is a small-molecule inhibitor of Aurora kinases A, B and C with potential antineoplastic activity. Aurora kinase inhibitor AMG 900 selectively binds to and inhibits the activities of Aurora kinases A, B and C, which may result in inhibition of cellular division and proliferation in tumor cells that overexpress these kinases. Group: Pharmaceutical. CAS No. 945595-80-2. Pack Sizes: 100 mg. Product ID: B2693-460871. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AMG 925 | AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body weight loss. The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, respectively. In addition, AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib). AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clinical responses. Group: Pharmaceutical. CAS No. 1401033-86-0. Pack Sizes: 25 mg. Product ID: B2693-463215. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ankaflavin | A pigment hs more anti-atherosclerosis effect and less side effect involving increasing creatinine phosphokinase activity. Group: Pharmaceutical. CAS No. 50980-32-0. Pack Sizes: 2 mg. Product ID: B2694-250736. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Apatinib mesylate | Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. Uses: Antineoplastic agents. Group: Pharmaceutical. CAS No. 1218779-75-9. Pack Sizes: 250 mg. Product ID: B2693-457664. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AR-A014418 | AR-A014418 is an ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK-3β), a serine/threonine protein kinase involved in multiple diseases including Alzheimer's disease and type 2 diabetes. Group: Pharmaceutical. CAS No. 487021-52-3. Pack Sizes: 25 mg. Product ID: B0084-258809. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AR-AO 14418-[d3] | AR-AO 14418-[d3] is a labelled analogue of AR-AO 14418, a Glycogen Synthase Kinase 3β (GSK-3β) inhibitor. Group: Pharmaceutical. CAS No. 1216908-63-2. Pack Sizes: 5 mg. Product ID: BLP-014119. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ARN-3236 | ARN-3236 is an orally available and selective inhibitor of salt-inducible kinase 2 (SIK2). Study shows that ARN-3236 inhibited the growth of 10 ovarian cancer cell lines at an IC50 of 0.8 to 2.6 μmol/L. Group: Pharmaceutical. CAS No. 1613710-01-2. Pack Sizes: 100 mg. Product ID: B1370-381366. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AS 1842856 | AS 1842856 is a potent and selective inhibitor of Forkhead box protein O1 transcription factor (FoxO1; IC50 = 33 nM). AS 1842856 reduces glucose production in dose manner via the inhibition of glucose-6 phosphatase and phosphoenolpyruvate carboxykinase mRNA levels in a rat hepatic cell line. AS 1842856 is promisingly to be a therapy of type 2 diabetes mellitus and obesity. Uses: Potential treatment of type 2 diabetes mellitus and obesity. Group: Pharmaceutical. CAS No. 836620-48-5. Pack Sizes: 200 mg. Product ID: B1370-054875. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Asciminib | Asciminib, also known as ABL-001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cell growth with an IC50 of 0.25 nM. Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. CAS No. 1492952-76-7. Pack Sizes: 10 mg. Product ID: B0084-007699. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AT13148 | AT13148 is an orally available multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. It can block phosphorylation of AKT, p70S6K, PKA, ROCK and SGK substrates, and induce apoptosis in cancer cells. Group: Pharmaceutical. CAS No. 1056901-62-2. Pack Sizes: 50 mg. Product ID: B0084-462670. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AT7519 HCl | AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. Group: Pharmaceutical. CAS No. 902135-91-5. Pack Sizes: 10 mg. Product ID: B0084-100271. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AT9283 | AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50= 3, 3, 1.2, 1.1, and 4 nM, respectively). It also potently (IC50 = <1 μM) inhibits serine/threonine kinases as well as receptor and non-receptor tyrosine kinases. Group: Pharmaceutical. CAS No. 896466-04-9. Pack Sizes: 10 mg. Product ID: B0084-100114. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AV-412 | AV-412 is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may suppress tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. Group: Pharmaceutical. CAS No. 451492-95-8. Pack Sizes: 20 mg. Product ID: B0084-324573. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AVL-292 | AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 1202757-89-8. Pack Sizes: 1 g. Product ID: B2693-462475. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib | Axitinib (AG013736) is a tyrosine kinase inhibitor developed by Pfizer. Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 319460-85-0. Pack Sizes: 5 g. Product ID: NP3631. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib Impurities | Axitinib Impurities hold paramount significance in pharmaceutical scrutiny, profoundly enhancing comprehension of axitinib, an essential tyrosine kinase inhibitor utilized in renal carcinoma treatment. These nuanced elements reveal drug stability, ensuring safety and therapeutic exactitude, thereby advancing cancer agent refinement and potentially elevating oncology treatment paradigms. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
